WTEN

Neuralace Medical Announces FDA Clearance of Axon Therapy for Chronic Painful Diabetic Neuropathy

Non-Invasive Magnetic Peripheral Nerve Stimulation (mPNS) Treatment Offers New Hope for PDN Patients SAN DIEGO, Jan. 11, 2024 /PRNewswire/ -- Neuralace Medical, Inc., an innovator in pain management ...
FierceBiotech

Neuralace weaves new diabetic neuropathy indication into noninvasive nerve stimulation tech

In mid-2021, after a decade of R&D, Neuralace Medical earned FDA clearance for its Axon Therapy, a noninvasive treatment option for chronic pain caused by nerve damage. The road to its next regulatory ...
Morningstar

ZAP Surgical Unveils the ZAP-Axon® Radiosurgery Planning System

New Generation Software Expected to Drive Best-In-Class Radiosurgery Brain Tumor Treatments ZAP Surgical Systems, Inc., a global leader in non-invasive robotic brain surgery, today announced the ...
Morningstar

ZAP Surgical’s ZAP-Axon Radiosurgery Planning System Receives U.S. FDA 510(k) and E.U. CE Clearance

ZAP Surgical Systems, Inc., a pioneer in non-invasive robotic brain surgery, today announced that its award-winning ZAP-Axon® Radiosurgery Planning System has received both U.S. FDA 510 (k) clearance ...
Finanznachrichten

Axon Neuroscience, a.s.: Axon Neuroscience's Immunotherapy Selected for a Landmark Combination-Therapy Alzheimer's Clinical Trial in US, Supported by a USD 151 Million Grant

Axon Neuroscience's active tau immunotherapy AADvac1 has been selected as the first tau-targeted therapy to enter a groundbreaking U.S. Alzheimer's disease phase 2 clinical trial (supported by a USD ...